Cambridge Epigenetix Raises $88 Million Series D Financing To Advance Best-In-Class Dna Sequencing Technology Platform
Cambridge Epigenetix Raises $88 Million Series D Financing To Advance Best-In-Class Dna Sequencing Technology Platform
11/02/21, 7:30 AM
Location
cambridge
Money raised
$88 million
Round Type
series d
Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionizing genome sequencing, today announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing investors such as GV, New Science Ventures, Ahren Innovation Capital and Sequoia.